Fox Run Management’s Roivant Sciences ROIV Stock Holding History

Fox Run Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,932	Closed	-$877K	–	1204
2025 Q3	$877K	Buy	+57,932	New	+$717K	0.14%	257

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fox Run Management's ROIV Position: Q4 2025 in Review

Fox Run Management sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 57,932 shares — an estimated $877K sold.

Fox Run Management first reported a position in ROIV in Q3 2025 and held it in 1 quarter. The position peaked at $877K in Q3 2025. 399 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

Fox Run Management reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
Fox Run Management sold 57,932 Roivant Sciences shares in Q4 2025, an estimated $877K.
Fox Run Management first reported a position in Roivant Sciences in Q3 2025 and held it in 1 quarter.
Fox Run Management's Roivant Sciences position peaked at $877K in Q3 2025.
399 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.